



## Pregnancy outcomes in women with preexisting thyroid diseases: a French cohort study

Marion Lecorguillé, Juliane Léger, Anne Forhan, Marie Cheminat,  
Marie-Noëlle Dufourg, Barbara Heude, Marie-Aline Charles

### ► To cite this version:

Marion Lecorguillé, Juliane Léger, Anne Forhan, Marie Cheminat, Marie-Noëlle Dufourg, et al.. Pregnancy outcomes in women with preexisting thyroid diseases: a French cohort study. *Journal of Developmental Origins of Health and Disease*, 2021, 12 (5), pp.704-713. 10.1017/S2040174420001051 . inserm-03082995

**HAL Id: inserm-03082995**

**<https://inserm.hal.science/inserm-03082995>**

Submitted on 18 Dec 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# **Pregnancy outcomes in women with pre-existing thyroid diseases: a French cohort study**

Short title: Pre-pregnancy thyroid diseases

Marion Lecorguillé<sup>✉1</sup>, Juliane Léger<sup>2,3,4</sup>, Anne Forhan<sup>1</sup>, Marie Cheminat<sup>5</sup>, Marie-Noëlle  
Dufourg<sup>5</sup>, Barbara Heude<sup>1\*</sup>, Marie-Aline Charles<sup>1,5\*</sup>

<sup>1</sup> Université de Paris, CRESS, INSERM, INRAE, F-75004 Paris, France

<sup>2</sup> National Institute of Health and Medical Research (INSERM), UMR INSERM NeuroDiderot, DHU Protect, F-75019 Paris, France.

<sup>3</sup> Paris University, F-75019 Paris, France.

<sup>4</sup> Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Pediatric Endocrinology Diabetology Department, Reference Center for Growth and Development Endocrine Diseases, F-75019 Paris, France.

<sup>5</sup> Ined-Inserm-EFS joint Unit ELFE, Paris, France

Corresponding Author's: Marion Lecorguillé, PhD student: [marion.lecorguille@inserm.fr](mailto:marion.lecorguille@inserm.fr)  
Marion Lecorguillé, INSERM-CRESS U1153, Equipe 6 EARoH 16 avenue Paul Vaillant-Couturier 94807 Villejuif Cedex

\* MA Charles and B Heude contributed equally to this work.

## Abstract

Women with thyroid diseases at the beginning of pregnancy may have suboptimal thyroid hormone levels because of potential difficulties in compensating for the physiological thyroid hormone changes occurring in pregnancy. Our objective was to study the association between pre-existing thyroid diseases, pregnancy complications and neonatal anthropometry.

In total, 16,395 women from the ELFE French longitudinal birth cohort were included, and 273 declared pre-pregnancy thyroid diseases. Associations were investigated with multivariable regression models, with adjustment for relevant potential confounders. Body mass index (BMI) was additionally adjusted for in a second stage.

As compared with other women, women with pre-pregnancy thyroid diseases were more frequently obese (19.6% vs 9.8%) and had greater odds of gestational diabetes development (OR = 1.58 [95% CI 1.08,2.30]) or had undergone treatment for infertility (OR = 1.57 [95% CI 1.07,2.31]). After adjustment for BMI, the association with gestational diabetes was no longer significant (OR = 1.27 [95% CI 0.86,1.88]). After excluding women with another medical history, those with pre-pregnancy thyroid diseases had increased odds of premature rupture of membranes (OR =1.51 [95% CI 1.01,2.25]). Children born from mothers with hypothyroidism before conception due to a disease or as a potential side effect of treatment had a smaller head circumference at birth than other children ( $\beta$ = -0.23 [95% CI -0.44,-0.01] cm).

In conclusion, pre-pregnancy thyroid diseases were associated with risk of infertility treatment, gestational diabetes, and premature rupture of membranes. The association between history of hypothyroidism and moderate adverse effects on fetal head circumference growth needs replication.

**Keywords:** medical history, thyroid diseases, hypothyroidism, pregnancy complications

## Introduction

Several physiological changes occur during pregnancy that could affect thyroid function. Adequate maternal thyroid function is especially important in early pregnancy and is crucial for the development of many organs, including the fetal brain <sup>1</sup>. During the first trimester of gestation, thyroid hormones from the mother are the only source for the developing embryo because fetal thyroid production begins at 12 to 14 amenorrhea weeks <sup>2</sup>. Maternal thyroid hormones circulate in fetal blood until birth <sup>1-3</sup>. Maternal thyroid hormone production increases by 20% to 50% to maintain a euthyroid state <sup>4</sup>. For women with pre-pregnancy hypothyroidism, levothyroxine treatment frequently needs to be increased during pregnancy and there is potential for periods of non-optimal treatment <sup>4,5</sup>.

The prevalence of thyroid disorders in pregnancy was evaluated in a recent meta-analysis according to diagnostic criteria and screening time. Among studies using the 2.5–97.5 percentile as a normal range for thyroid-stimulating hormone, prevalence rates were 0.5% for overt hypothyroidism, 3.5% for subclinical hypothyroidism and, in the first trimester, 0.9% for overt hyperthyroidism and 2.2% for subclinical hyperthyroidism <sup>6</sup>. These pathologies must be recognized because they may be associated with pregnancy complications and fetal development <sup>1,4,7</sup>.

In several studies, overt and subclinical hypothyroidism have been associated with adverse outcomes, including miscarriage, haemorrhage, premature rupture of membranes, gestational hypertension, diabetes, prematurity, caesarean section, induced labor and reduced fertility <sup>4,5,8-14</sup>. The neonatal complications are risk of intrauterine growth retardation and low or large birthweight <sup>4,9,15</sup>. The adverse effects of subclinical hypothyroidism on pregnancy

Pre-pregnancy thyroid diseases outcomes are still not clear, and most of these complications are related to overt hypothyroidism and chronic autoimmune thyroiditis <sup>16</sup>. Maternal hyperthyroidism has been associated with increased risk of infertility, premature birth, gestational hypertension and pre-eclampsia, placenta abruption and induced labor, intrauterine growth retardation and fetal hyperthyroidism <sup>4,9,14,17–20</sup>. The associations between thyroid autoantibodies and miscarriage and preterm birth are also well established <sup>4,21,22</sup>.

However, few studies have evaluated the risk of complications during pregnancy related specifically to pre-pregnancy thyroid diseases <sup>23–25</sup>. In women with pre-pregnancy thyroid diseases, pregnancy may lead to suboptimal thyroid hormone concentration because of the inability of the thyroid gland to adapt to physiological changes at the beginning of pregnancy due to the disease itself or to its treatment <sup>9</sup>. Women with a history of thyroidectomy, radioactive iodine treatment, goiter or hypothyroidism, or Graves' disease need appropriate medical management of thyroid function during pregnancy <sup>4</sup>. Thyroid diseases are heterogenous. However, whatever the disorder, these diseases were known before pregnancy and should have been treated before or adequately managed during pregnancy.

Thus, our aim was to explore whether or not, as a group, women with pre-pregnancy thyroid disease had similar pregnancy outcomes as women without such a history. Taking advantage of the data for the French national birth cohort ELFE (*Etude Longitudinale Française depuis l'Enfance*), we described pregnancy and fetal outcomes in women with and without known pre-pregnancy thyroid diseases.

## Methods

### *Study design*

The present analysis relies on data from the ELFE study, the first French national longitudinal birth cohort. The rationale and design of the ELFE cohort were previously described in detail

<sup>26</sup>. Briefly, participation in the cohort was proposed to women giving birth in 349 maternity hospitals randomly selected among the 544 public and private maternity hospitals in metropolitan France. Recruitment took place on 25 selected days during 2011. The ELFE cohort inclusion criteria were birth at  $\geq 33$  amenorrhea weeks, single or twin infants, mother  $\geq 18$  years old, giving informed consent and not having plans to leave metropolitan France within 3 years. Among eligible mothers, 51% agreed to participate.

The ELFE study was approved by the ethics committee of Créteil (CPP), the national committee on information concerning health research (CCTIRS) and the Data Protection Authority (*Commission Nationale de l'Informatique et des Libertés* [CNIL]).

### ***Data collection***

Research assistants collected information after birth from maternal medical records and during a face-to-face interview while the mother was in the maternity ward.

### **Pre-pregnancy thyroid diseases**

Research assistants collected the diagnosis of severe maternal pre-pregnancy diseases or disability (excluding history of chronic or gestational diabetes or hypertension for which dedicated questions were asked) from medical files where such information is recorded as part of the routine medical history assessment.

From these data, we extracted all diseases potentially associated with thyroid dysfunction. All diseases were coded according to International Classification of Diseases, 10<sup>th</sup> Revision. In total, 273 women presented thyroid diseases before pregnancy; we classified these women into three groups: women with 1) hypothyroidism due to a disease or as a potential side effect of treatment (Hashimoto's disease, hypothyroidism unspecified, no thyroid, thyroidectomy, thyroid cancer and women with levothyroxine treatment; n=196), 2) hyperthyroidism (Grave's disease, hyperthyroidism unspecified; n=49) and 3) other thyroid diseases (goiter,

Pre-pregnancy thyroid diseases nodules, thyroid dysfunction or thyroid diseases unspecified, n=28). We combined women with thyroidectomy (n=16) and thyroid cancer (n=4) in the first group because of the small number of cases.

### Pregnancy and fetal outcomes

Among all the data related to pregnancy complications, we selected for analyses the following outcomes with a minimum prevalence of 7% in the population, which ensured a power of 90% to detect a minimal relative risk of 1.75 for these diseases with alpha 5% (power increases for more prevalent outcomes): premature rupture of membranes (12 hr before labor onset), gestational diabetes, induction of labor (spontaneous labor, induction of labor, elective caesarean section), maternal hospitalization and mode of delivery (spontaneous vaginal delivery, assisted vaginal delivery [forceps, vacuum, spatula], caesarean section). Gestational hypertension and premature birth (< 37 amenorrhea weeks) were not studied because of too few cases in the exposed group. We also studied treatment for infertility before pregnancy. Birth weight, birth length, head circumference and gestational age at birth were treated as continuous variables. Sex and gestational age-specific z scores customized for maternal weight, height and parity were computed using a method adapted for the French 2010 national perinatal survey, from that proposed by Gardosi <sup>27</sup>. Percentiles were then derived and used to define fetal growth categories: small for gestational age (SGA, <10<sup>th</sup> percentile), appropriate for gestational age (AGA, 10<sup>th</sup> to 90<sup>th</sup> percentile) and large for gestational age (LGA, >90<sup>th</sup> percentile).

### Other maternal variables

Sociodemographic data included maternal age (continuous), parity, education level (tertiary education as reference vs primary and secondary), professional status (employed or student,

Pre-pregnancy thyroid diseases  
housewife or parental leave, and other, including unemployment), living with a partner (yes vs no), place of birth (born in France vs other country), and maternity unit level.

Health-related variables included state health insurance coverage (regular or specific to precarious situations), smoking during pregnancy (yes vs no), number of prenatal consultations ( $< 7$ ,  $7-9$ ,  $\geq 9$ ), ultrasounds ( $\leq 5$ ,  $> 5$ ) and maternal pre-pregnancy weight and height. Body mass index (BMI) was calculated as weight (kg) divided by the height<sup>2</sup> (m<sup>2</sup>) and divided into 4 categories according to World Health Organization thresholds: underweight,  $<18.5$  kg/m<sup>2</sup>; normal weight,  $18.5$  to  $<25$  kg/m<sup>2</sup>; overweight,  $25.0$  to  $<30$  kg/m<sup>2</sup>; and obesity,  $\geq 30$  kg/m<sup>2</sup>.

### ***Population selected for analysis***

In total, 55 included mothers withdrew from the ELFE cohort and asked for data deletion. Mothers of twins ( $n=287$ ) or with missing medical records ( $n=175$ ) or face-to-face maternal questionnaires ( $n=59$ ) were excluded. For women with available medical records, we excluded 1070 with missing data on medical history. Figure 1 displays the flow chart for the population selection process. We grouped the selected women into two categories: 16,122 women with no medical history of thyroid diseases and 273 with pre-pregnancy thyroid diseases as described above.

### ***Statistical analysis***

#### **Descriptive analysis**

We compared sociodemographic characteristics and pregnancy outcomes between patients with and without pre-pregnancy thyroid diseases by chi-square test for categorical variables and ANOVA for continuous variables.



### Multivariable analysis

Multivariable logistic, linear and polytomic regression analyses were used to investigate the association between thyroid diseases and pregnancy outcomes, estimating odds ratios (ORs) and 95% confidence intervals (CIs). We first adjusted our analyses for potential confounders, namely parity, smoking during pregnancy, maternal age, and maternal education. For birth head circumference, weight and length, we additionally adjusted for gestational age and sex. Second, we adjusted for pre-pregnancy BMI as a continuous variable and investigated its potential role as an intermediate factor in the observed associations. We also introduced an interaction term between pre-pregnancy BMI and pre-pregnancy thyroid diseases to test whether the effect of a history of thyroid disease differed by maternal pre-pregnancy BMI.

### Sensitivity analysis

To examine whether the observed relations were due to the thyroid diseases themselves and not other pre-pregnancy diseases, which could be more frequent in our affected group, we repeated our main analysis after excluding women with other medical histories such as autoimmune diseases, history of diabetes, hypertension, and other diseases known to affect pregnancy outcomes.

Because different types of thyroid disorders may be related to specific risks, we separately analysed data for women with pre-pregnancy thyroid diseases associated with hypothyroidism (as defined in the Data collection section) as compared with women without pre-pregnancy thyroid diseases. Women with other thyroid diseases (hyperthyroidism or unspecified) were too few to be considered in a separate analysis and were excluded from this analysis.

## Results

### *Population characteristics*

The characteristics of the women are summarized in **Table 1**. Women with pre-pregnancy thyroid diseases were older, had a higher level of education, were twice as frequently obese, and less often smoked during pregnancy than women without pre-pregnancy thyroid diseases. The two groups were similar in employment status, country of birth or personal health insurance and number of prenatal consultations, but women with pre-pregnancy thyroid diseases had more ultrasounds during pregnancy. Women with pre-pregnancy thyroid diseases more frequently underwent treatment for infertility and had gestational diabetes than women without thyroid diseases (12% vs 7%,  $p < 0.01$ , for both) (**Table S1**).

### *Multivariable analysis*

After adjustment for the first set of confounders, the occurrence of pre-pregnancy thyroid diseases was associated with a 1.6-fold increased risk of infertility treatment and gestational diabetes (95% CI 1.07,2.31) and (95% CI 1.08,2.30) (**Table 2**) but was not associated with mode of delivery, induction of labour, birth weight or length or head circumference. After additional adjustment for BMI, the risk of gestational diabetes was no longer significant (OR =1.27 [95% CI 0.86,1.88]). The interaction between BMI and pre-pregnancy thyroid diseases was not significant for any of the pregnancy outcomes considered ( $p > 0.05$ , data not shown).

### Exclusion of other medical history

We excluded women with a history of diseases other than thyroid diseases from the thyroid diseases group ( $n=62$ ) and control group ( $n=1995$ ), which left 211 and 14,127 women in each group (**Table 3**). Risk of premature rupture of membranes was increased for women with pre-

Pre-pregnancy thyroid diseases  
pregnancy thyroid diseases (OR = 1.51 [95% CI 1.01,2.25]) (p =0.04). The occurrence of pre-pregnancy thyroid diseases was no longer associated with infertility or gestational diabetes.

#### Restriction to cases of hypothyroidism

We restricted the analysis to the comparison of women with hypothyroidism before pregnancy (n=196) to women without thyroid diseases before pregnancy. On univariate analysis, infertility treatment, gestational diabetes and premature rupture of membranes were significantly more frequent for women in the hypothyroidism group (p < 0.05; **Table 4**). In total, 20.4% of the women in this group were overweight and 20.9% were obese at conception as compared with 17.2% and 9.8% of women without thyroid diseases before pregnancy. After adjustment on educational level, parity, maternal age and smoking, the risks remained significantly increased for the same pregnancy complications (data not shown). After an additional adjustment for BMI, associations with premature rupture of membranes and infertility treatment (both p=0.05) remained, but the association with gestational diabetes was decreased (p=0.4) (**Table 4**). Mother's hypothyroidism before pregnancy was associated with reduced infant head circumference at birth ( $\beta$ = -0.20 [95% CI -0.39,-0.01] cm, p=0.04). After excluding women with a history of diseases other than thyroid diseases, 149 women were in the pre-pregnancy hypothyroidism group and 14,127 the comparison group. Mother's hypothyroidism was associated with increased risk of premature rupture of membranes and slightly reduced infant head circumference at birth ( $\beta$ = -0.23 [95% CI -0.44,-0.01], p = 0.04) cm (**Table 5**).

## **Discussion**

Our study showed an increased risk of infertility treatment and gestational diabetes and greater frequency of obesity for women with than without pre-pregnancy thyroid diseases.

After excluding women with other medical conditions known to interfere with pregnancy, the risk of premature rupture of membranes was increased. Finally, when we specifically investigated women with hypothyroidism before pregnancy, due to a disease or as a potential side effect of treatment, their offspring had a smaller head circumference at birth, on average.

Our findings are consistent with the consequences of thyroid dysfunction. Hypothyroidism, either primary or secondary to treatment of thyroid or pituitary diseases, is often associated with excess weight <sup>28</sup>. Indeed 19.6% versus 9.8% of our women with and without pre-pregnancy thyroid diseases were obese. In addition, thyroid function may be more often screened in obese patients. Obesity is associated with insulin resistance, hyperinsulinemia and risk of developing gestational diabetes <sup>29</sup>. It can explain the increased risk of gestational diabetes in our women with pre-pregnancy thyroid diseases because the OR decreased from 1.58 (adjusted model 1) to 1.27 after adjustment for BMI at the beginning of pregnancy. Thyroid hormones are also essential for energy homeostasis, and a dysfunction could affect metabolism: blood pressure, and high-density lipoprotein cholesterol, triglycerides and glucose levels. Thyroid diseases have been found associated with increased blood glucose levels, insulin resistance, and reduced insulin clearance <sup>30</sup>.

Reduced fertility is also a well-known consequence of obesity <sup>29</sup>, but adjustment for BMI did not modify the risk of infertility treatment associated with pre-pregnancy thyroid diseases. Conversely, excluding women with other diseases reduced the risk in our study, which indicates that some of these diseases, such as autoimmune, hypothalamic or pituitary anomalies, contribute to the risk of infertility. Care for infertility includes screening for thyroid dysfunction and increases the probability of a diagnosis of thyroid disease before pregnancy. Thus, reverse causality is another potential explanation for our observed association between pre-pregnancy thyroid disease and infertility. In some studies, autoimmune thyroiditis with the presence of anti-thyroid peroxidase antibodies have been

Pre-pregnancy thyroid diseases found associated with decreased fertility and miscarriage <sup>16</sup>. Thyroid dysfunction by itself has also been found to affect the physiology of reproduction, miscarriage and ovulation disorders <sup>12</sup>.

An association with premature rupture of membranes was described in several studies of women with subclinical hypothyroidism <sup>11,31</sup> or positive antibodies <sup>13</sup>. The pathophysiological mechanisms underlying these associations are unclear but may include a direct effect of thyroid antibodies by an antibody-mediated cytotoxic effect <sup>22</sup>, a subtle thyroid dysfunction and/or a more generalized autoimmune dysfunction <sup>16,22</sup>. However, in our study, the association between pre-pregnancy thyroid diseases and premature rupture of membranes remained after excluding women with other medical conditions including autoimmune diseases.

We found no association of pre-pregnancy thyroid diseases with gestational age of birth, induction of labour or caesarean delivery, in contrast to other studies comparing women with manifest thyroid dysfunction and other women <sup>5,8,9,13,14</sup>. In our study, women with pre-pregnancy thyroid diseases should have been monitored for thyroid hormone concentrations and we expected more subtle abnormalities than for diseases discovered during pregnancy.

Contrary to previous studies <sup>10,15</sup>, we did not find any association of pre-pregnancy thyroid diseases with infant birthweight. Women with the more severe fetal outcomes may have been less likely to participate in the study. However, we did not expect such severe cases in relation with pre-pregnancy thyroid disease. Nevertheless, offspring of mothers with pre-pregnancy hypothyroidism had slightly smaller head circumference at birth than those of women without pre-pregnancy thyroid diseases after adjustment for maternal BMI (Table 5). A few studies have published results on birth head circumference. Overt and subclinical hypothyroidism disease have been associated with abnormal fetal growth and a decrease in head circumference <sup>32,33</sup>. However, other results reported null associations with head

Pre-pregnancy thyroid diseases circumference <sup>34</sup>. The relation between maternal thyroid dysfunction and neuroimaging outcomes for offspring has been investigated. One study showed an inverted U-shaped association between free thyroxine maternal concentration and total gray-matter volume and cortex volume in children <sup>35</sup>. Small head circumference is known to increase the risk of subnormal neurodevelopment, <sup>36</sup> and long-term follow-up of the neurodevelopment of these children is warranted. Isolated hypothyroxinaemia (decreased free thyroxine and normal thyroid-stimulating hormone levels) is predominantly associated with adverse neurobehavioral development in children <sup>7</sup>, risk of poor verbal and non-verbal cognitive development in children at 18 and 30 months <sup>37</sup> and delayed psychomotor development at 1 and 2 years <sup>38</sup>. Another recent study highlighted the importance of adequate maternal iodine status in the early stages of pregnancy for optimal development of verbal IQ <sup>39</sup>.

### ***Strengths and limitations***

The strengths of our study are its nationwide scope and the availability of data from medical records. However, the medical history information still depends on the accuracy of the physician interview and the memory of the women, and its presence in the maternity medical record depends on the women's access to health care. A history of thyroid disease was indeed more frequently reported by women with increased level of education, and missing information in the medical history was more frequent for women in disadvantaged situations.

The lack of information on thyroid function and treatment is another limitation. There was no attempt to search for laboratory or imaging exams or related treatments that could confirm the diagnosis and provide information about thyroid function because the amount of data collected at inclusion in the ELFE cohort was already large. More specific studies on the topic with thyroid hormone measurements are warranted.

Moreover, we did not have information on the time between diagnosis and pregnancy that may induce different severity of thyroid diseases. Some of the asymptomatic women may

Pre-pregnancy thyroid diseases present undiagnosed antibody positivity without thyroid dysfunction, and some women declaring pre-pregnancy hyperthyroidism may have fully recovered from the disease. In our study, although our cohort was large, we could not separately evaluate the effects of pre-pregnancy hyperthyroidism or thyroiditis on pregnancy outcome because of the limited number of affected women. Another limitation was that we were unable to study some outcomes (hypertension, prematurity) because of too few cases in the exposed group. We did not have information on treatment of thyroid disease during pregnancy and whether fetal outcomes differ between women with adequate and non-adequate treated disease. However, our results represent the overall effect and indicate that the average situation in France may not be optimal. Finally, only live births ( $\geq 33$  amenorrhea weeks) were included in the ELFE cohort. If pre-pregnancy thyroid diseases affect the probability of miscarriage or extreme prematurity, our results could be biased, probably by underestimating the effect of thyroid diseases.

Few epidemiologic studies have evaluated the risk of complications during pregnancy related specifically to thyroid diseases before conception. Our observations reflect the complexity of thyroid function and dysfunction on fertility and pregnancy outcome in women with pre-existing thyroid diseases. Particular care is required in the management of these women. Knowledge about the consequences of thyroid dysfunction should be optimized by educational strategies to improve medical care and compliance with treatment. Normal thyroid function during pre-conceptional phase and throughout pregnancy should be a key objective for the prevention of pregnancy complications and prevention of morbidity in fetuses and neonates. Moreover, in line with the developmental origins of health and disease theory, pre-pregnancy thyroid pathologies may be among the early conditions that could have long-term consequences on cognitive development <sup>39</sup>. Optimal maternal thyroid function is necessary for offspring development, and further studies are needed to assess

Pre-pregnancy thyroid diseases  
neurodevelopment outcomes of children of women with pre-pregnancy thyroid diseases and  
to understand the underlying mechanisms<sup>40,41</sup>.

## **Conclusion**

In our study, pre-pregnancy thyroid diseases were associated with risk of infertility treatment, gestational diabetes, and premature rupture of membranes. The association between history of hypothyroidism due to a disease or as a potential side effect of surgical or cancer treatment and moderate adverse effects on fetal head circumference growth needs replication with a larger number of participants.

## **Acknowledgments**

The ELFE survey is a joint project between the French Institute for Demographic Studies (INED) and the National Institute of Health and Medical Research (INSERM), in partnership with the French blood transfusion service (Etablissement français du sang, EFS), Santé publique France, the National Institute for Statistics and Economic Studies (INSEE), the Direction générale de la santé (DGS, part of the Ministry of Health and Social Affairs), the Direction générale de la prévention des risques (DGPR, Ministry for the Environment), the Direction de la recherche, des études, de l'évaluation et des statistiques (DREES, Ministry of Health and Social Affairs), the Département des études, de la prospective et des statistiques (DEPS, Ministry of Culture), and the Caisse nationale des allocations familiales (CNAF), with the support of the Ministry of Higher Education and Research and the Institut national de la jeunesse et de l'éducation populaire (INJEP).

We thank the members of the ELFE Ined-Inserm-EFS joint unit and above all the families involved in the ELFE cohort without whom this study would not have been possible.

## **Financial support**



Marion Lecorguillé received a scholarship from the Open Health Institute for this work.

The ELFE study receives a government grant managed by the National Research Agency under the “Investissements d’avenir” program (ANR 11 EQPX 0038).

## Conflicts of Interest

The authors have nothing to disclose

## Ethical Standards

The authors assert that all procedures contributing to this work have been approved by the ethics committee of Créteil (CPP), the national committee on information concerning health research (CCTIRS) and the Data Protection Authority (*Commission Nationale de l’Informatique et des Libertés*, CNIL).

## References

1. Springer D, Jiskra J, Limanova Z, Zima T, Potlukova E. Thyroid in pregnancy: From physiology to screening. *Crit Rev Clin Lab Sci*. 2017;54(2),102-116. doi:10.1080/10408363.2016.1269309
2. Morreale de Escobar G, Obregon MJ, Escobar del Rey F. Role of thyroid hormone during early brain development. *Eur J Endocrinol*. 2004;151 Suppl 3,U25-37.
3. Korevaar TIM, Chaker L, Jaddoe VWV, Visser TJ, Medici M, Peeters RP. Maternal and Birth Characteristics Are Determinants of Offspring Thyroid Function. *J Clin Endocrinol Metab*. 2016;101(1),206-213. doi:10.1210/jc.2015-3559
4. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. *Thyroid*. 2017;27(3),315-389. doi:10.1089/thy.2016.0457
5. Léger J, dos Santos S, Larroque B, Ecosse E. Pregnancy outcomes and relationship to treatment adequacy in women treated early for congenital hypothyroidism: a longitudinal population-based study. *J Clin Endocrinol Metab*. 2015;100(3),860-869. doi:10.1210/jc.2014-3049
6. Dong A, Stagnaro-Green A. Differences in Diagnostic Criteria Mask the True Prevalence of Thyroid Disease in Pregnancy - A Systematic Review and Meta-Analysis. *Thyroid Off J Am Thyroid Assoc*. November 2018. doi:10.1089/thy.2018.0475

7. Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new insights in diagnosis and clinical management. *Nat Rev Endocrinol*. 2017;13(10),610-622. doi:10.1038/nrendo.2017.93
8. Casey BM, Dashe JS, Wells CE, et al. Subclinical Hypothyroidism and Pregnancy Outcomes: *Obstet Gynecol*. 2005;105(2),239-245. doi:10.1097/01.AOG.0000152345.99421.22
9. Nazarpour S, Ramezani Tehrani F, Simbar M, Azizi F. Thyroid dysfunction and pregnancy outcomes. *Iran J Reprod Med*. 2015;13(7),387-396.
10. Teng W, Shan Z, Patil-Sisodia K, Cooper DS. Hypothyroidism in pregnancy. *Lancet Diabetes Endocrinol*. 2013;1(3),228-237. doi:10.1016/S2213-8587(13)70109-8
11. Maraka S, Ospina NMS, O'Keeffe DT, et al. Subclinical Hypothyroidism in Pregnancy: A Systematic Review and Meta-Analysis. *Thyroid*. 2016;26(4),580-590. doi:10.1089/thy.2015.0418
12. Krassas GE. Thyroid disease and female reproduction. *Fertil Steril*. 2000;74(6),1063-1070.
13. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, et al. Maternal Thyroid Hypofunction and Pregnancy Outcome: *Obstet Gynecol*. 2008;112(1),85-92. doi:10.1097/AOG.0b013e3181788dd7
14. Männistö T, Mendola P, Grewal J, Xie Y, Chen Z, Laughon SK. Thyroid Diseases and Adverse Pregnancy Outcomes in a Contemporary US Cohort. *J Clin Endocrinol Metab*. 2013;98(7),2725-2733. doi:10.1210/jc.2012-4233
15. Hou J, Yu P, Zhu H, et al. The impact of maternal hypothyroidism during pregnancy on neonatal outcomes: a systematic review and meta-analysis. *Gynecol Endocrinol*. 2016;32(1),9-13. doi:10.3109/09513590.2015.1104296
16. De Leo S, Pearce EN. Autoimmune thyroid disease during pregnancy. *Lancet Diabetes Endocrinol*. 2018;6(7),575-586. doi:10.1016/S2213-8587(17)30402-3
17. Karakosta P, Alegakis D, Georgiou V, et al. Thyroid Dysfunction and Autoantibodies in Early Pregnancy Are Associated with Increased Risk of Gestational Diabetes and Adverse Birth Outcomes. *J Clin Endocrinol Metab*. 2012;97(12),4464-4472. doi:10.1210/jc.2012-2540
18. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. *Lancet Diabetes Endocrinol*. 2013;1(3),238-249. doi:10.1016/S2213-8587(13)70086-X
19. Laurberg P, Bornaud C, Karmisholt J, Orgiazzi J. Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. *Eur J Endocrinol*. 2009;160(1),1-8. doi:10.1530/EJE-08-0663
20. Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, et al. Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. *Clin Endocrinol (Oxf)*. 2001;54(3),365-370.

21. van den Boogaard E, Vissenberg R, Land JA, et al. Significance of (sub)clinical thyroid dysfunction and thyroid autoimmunity before conception and in early pregnancy: a systematic review. *Hum Reprod Update*. 2011;17(5),605-619. doi:10.1093/humupd/dmr024
22. Thangaratinam S, Tan A, Knox E, Kilby MD, Franklyn J, Coomarasamy A. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. *BMJ*. 2011;342(may09 1),d2616-d2616. doi:10.1136/bmj.d2616
23. Hirsch D, Levy S, Nadler V, Kopel V, Shainberg B, Toledano Y. Pregnancy outcomes in women with severe hypothyroidism. *Eur J Endocrinol*. 2013;169(3),313-320. doi:10.1530/EJE-13-0228
24. Reid SM, Middleton P, Cossich MC, Crowther CA, Bain E. Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy. *Cochrane Database Syst Rev*. 2013;(5),CD007752. doi:10.1002/14651858.CD007752.pub3
25. Earl R, Crowther CA, Middleton P. Interventions for hyperthyroidism pre-pregnancy and during pregnancy. *Cochrane Database Syst Rev*. 2013;(11),CD008633. doi:10.1002/14651858.CD008633.pub3
26. Charles MA, Thierry X, Lanoe J-L, et al. Cohort Profile: The French National cohort of children ELFE: birth to 5 years. *Int J Epidemiol*. November 2019. doi:10.1093/ije/dyz227
27. Ego A, Prunet C, Blondel B, Kaminski M, Goffinet F, Zeitlin J. [Customized and non-customized French intrauterine growth curves. II - Comparison with existing curves and benefits of customization]. *J Gynecol Obstet Biol Reprod (Paris)*. 2016;45(2),165-176. doi:10.1016/j.jgyn.2015.08.008
28. Léger J, Ecosse E, Roussey M, Lanoë JL, Larroque B, French Congenital Hypothyroidism Study Group. Subtle health impairment and socioeducational attainment in young adult patients with congenital hypothyroidism diagnosed by neonatal screening: a longitudinal population-based cohort study. *J Clin Endocrinol Metab*. 2011;96(6),1771-1782. doi:10.1210/jc.2010-2315
29. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. *BMJ*. 2017;356:j1. doi:10.1136/bmj.j1
30. Iwen KA, Schröder E, Brabant G. Thyroid Hormones and the Metabolic Syndrome. *Eur Thyroid J*. 2013;2(2),83-92. doi:10.1159/000351249
31. Chen L-M, Du W-J, Dai J, et al. Effects of Subclinical Hypothyroidism on Maternal and Perinatal Outcomes during Pregnancy: A Single-Center Cohort Study of a Chinese Population. Gao C-Q, ed. *PLoS ONE*. 2014;9(10),e109364. doi:10.1371/journal.pone.0109364
32. Blazer S, Moreh-Waterman Y, Miller-Lotan R, Tamir A, Hochberg Z. Maternal hypothyroidism may affect fetal growth and neonatal thyroid function. *Obstet Gynecol*. 2003;102(2),232-241.

33. Su P-Y, Huang K, Hao J-H, et al. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China. *J Clin Endocrinol Metab.* 2011;96(10),3234-3241. doi:10.1210/jc.2011-0274
34. Männistö T, Vääräsmäki M, Pouta A, et al. Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective population-based cohort study. *J Clin Endocrinol Metab.* 2009;94(3),772-779. doi:10.1210/jc.2008-1520
35. Korevaar TIM, Muetzel R, Medici M, et al. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. *Lancet Diabetes Endocrinol.* 2016;4(1),35-43. doi:10.1016/S2213-8587(15)00327-7
36. Lundgren EM, Cnattingius S, Jonsson B, Tuvemo T. Intellectual and psychological performance in males born small for gestational age with and without catch-up growth. *Pediatr Res.* 2001;50(1),91-96. doi:10.1203/00006450-200107000-00017
37. Henrichs J, Bongers-Schokking JJ, Schenk JJ, et al. Maternal Thyroid Function during Early Pregnancy and Cognitive Functioning in Early Childhood: The Generation R Study. *J Clin Endocrinol Metab.* 2010;95(9),4227-4234. doi:10.1210/jc.2010-0415
38. Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, de Vijlder JJ. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. *Clin Endocrinol (Oxf).* 2003;59(3),282-288.
39. Levie D, Korevaar TIM, Bath SC, et al. Association of Maternal Iodine Status With Child IQ: A Meta-Analysis of Individual Participant Data. *J Clin Endocrinol Metab.* 2019;104(12),5957-5967. doi:10.1210/jc.2018-02559
40. Haddow JE. Maternal Thyroxine and Fetal Brain Development: The Latest Chapter, a Look Back, and Considerations for the Future. *J Clin Endocrinol Metab.* 2013;98(4),1388-1390. doi:10.1210/jc.2013-1646
41. Korevaar TIM, Tiemeier H, Peeters RP. Clinical associations of maternal thyroid function with fetal brain development: Epidemiological interpretation and overview of available evidence. *Clin Endocrinol (Oxf).* April 2018. doi:10.1111/cen.13724

**Figure 1:** Flow of the women in the study. Selection of women with pre-pregnancy thyroid diseases.

Table 1: Characteristics of ELFE women with and without pre-pregnancy thyroid diseases.

Demographic data	N	No thyroid diseases (N=16,122)	Pre-pregnancy thyroid diseases (N=273)	P-value
<b>Maternal age (years)</b>	16,387	30.6 ± 5.1	32.0 ± 5.0	<.001
<b>Maternity unit level</b>	16,395			
Level 2 and 3 centers		76.9 (12393)	80.6 (220)	0.15
<b>Place of birth (France)</b>	16,297	87.2 (13970)	89.3 (242)	0.30
<b>Maternal education</b>	16,392			
Tertiary education		59.9 (9648)	66.7 (182)	0.023
<b>Living with a partner (yes)</b>	16,321	94.5 (15169)	96.7 (263)	0.12
<b>Social health insurance coverage</b>	16,326			
Related to precarious situations		8.5 (1362)	7.0 (19)	0.39
<b>Employment status</b>	16,027			0.14
Employed, student		80.2 (12635)	83.4 (226)	
Housewife, parental leave		11.7 (1847)	11.8 (32)	
Other, unemployment		8.1 (1274)	4.8 (13)	
<b>Smoking during pregnancy</b>	16,300	20.5 (3286)	15.1 (41)	0.028
<b>Pre-pregnancy BMI*</b>	16,201			<.001
Underweight		7.9 (1263)	5.5 (15)	
Normal weight		65.0 (10355)	54.6 (148)	
Overweight		17.2 (2746)	20.3 (55)	
Obese		9.8 (1566)	19.6 (53)	
<b>Primiparous</b>	16,317	45.8 (7350)	43.4 (118)	0.43
<b>Number of ultrasounds</b>	15,926			0.01
≤ 5		76.7 (12018)	70.2(186)	
>5		23.3 (3643)	29.8 (79)	
<b>Prenatal consultations</b>	16,150			0.41
< 7		10.4 (1645)	9.7 (26)	
7–9		68.4 (10859)	65.7 (176)	
> 9		21.3 (3378)	24.6 (66)	

Data are % (n) or mean ± SD.

\*Body mass index (BMI) was classified according to the World Health Organisation as underweight, <18.5 kg/m<sup>2</sup>; normal weight, 18.5 to <25 kg/m<sup>2</sup>; overweight, 25.0 to <30 kg/m<sup>2</sup>; obesity, ≥30 kg/m<sup>2</sup>.

Table 2: Multivariable analysis of pregnancy and birth outcomes for women with and without pre-pregnancy thyroid diseases before and after adjustment for confounding factors and pre-pregnancy BMI.

<b>Outcomes*</b>	<b>Unadjusted model</b>	<b>Adjusted model 1</b>	<b>Adjusted model 2</b>
<b>Categorical variables</b>	<b>OR [95% CI]</b>	<b>OR [95% CI]</b>	<b>OR [95% CI]</b>
<b>Infertility treatment</b>	1.74 [1.19,2.55] <sup>a</sup>	1.57 [1.07,2.31] <sup>b</sup>	1.55 [1.05,2.28] <sup>b</sup>
<b>Gestational diabetes</b>	1.68 [1.15,2.44] <sup>a</sup>	1.58 [1.08,2.30] <sup>b</sup>	1.27 [0.86,1.88]
<b>Hospitalization during pregnancy</b>	1.28 [0.94,1.74]	1.34 [0.99,1.83]	1.31 [0.96,1.79]
<b>Induction of labor</b>			
Spontaneous labor	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Induction	1.10 [0.81,1.49]	1.09 [0.80,1.48]	1.01 [0.74,1.37]
Prelabor caesarean section	1.34 [0.90,1.97]	1.23 [0.83,1.82]	1.10 [0.74,1.64]
<b>Mode of birth</b>			
Vaginal delivery	1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Assisted delivery**	1.05 [0.73,1.51]	1.06 [0.73,1.56]	1.07 [0.73,1.57]
Caesarean section	1.22 [0.90,1.65]	1.14 [0.84,1.56]	1.02 [0.74,1.40]
<b>Premature rupture of membranes</b>	1.28 [0.89,1.85]	1.27 [0.87,1.85]	1.27 [0.87,1.85]
<b>Birth weight categories***</b>			
AGA	1.00 (Reference)	1.00 (Reference)	NA
SGA	0.82 [0.52,1.29]	0.86 [0.54,1.35]	
LGA	1.03 [0.69,1.54]	1.03 [0.69,1.53]	
<b>Quantitative variables</b>	<b>β [95% CI]</b>	<b>β [95% CI]</b>	<b>β [95% CI]</b>
<b>Gestational age (amenorrhea weeks)</b>	0.03 [-0.14,0.20]	0.02 [-0.15,0.19]	0.01 [-0.16,0.18]
<b>Birth weight (g)</b>	41.25 [-15.95,98.45]	29.06 [-18.86,76.98]	8.29 [-39.25,55.82]
<b>Birth length (cm)</b>	0.27 [0.002,0.54] <sup>b</sup>	0.19 [-0.04,0.42]	0.15 [-0.08,0.38]
<b>Head circumference (cm)</b>	-0.005 [-0.18,0.17]	-0.04 [-0.20,0.13]	-0.08 [-0.24,0.08]

Data are odds ratios (ORs) or beta (β) values and 95% confidence intervals (CIs).

Model 1: adjusted for maternal education level, maternal age, parity, smoking during pregnancy and infant sex and gestational age for head circumference, birth weight and birth length. Model 2: model 1 and adjustment for BMI as a continuous variable.

\* Maximal N for outcome in unadjusted model (N=16,302) and minimal N in adjusted model 2 (N=14,507). When the sample was restricted to women included in the 3 models, results were similar as above for all 3 models.

\*\* Assisted delivery: forceps, spatulas, vacuum

\*\*\* A customized standard to assess fetal growth: SGA, small for gestational age (< 10<sup>th</sup> percentile); AGA, appropriate for gestational age (10<sup>th</sup> to 90<sup>th</sup> percentile); LGA, large for gestational age (>90<sup>th</sup> percentile). (see methods)

<sup>a</sup> p<.01 <sup>b</sup> p<.05. NA: not applicable (model already adjusted for BMI)

Table 3: Multivariable analysis of pregnancy and birth outcomes for women with pre-pregnancy thyroid diseases and without pre-pregnancy thyroid diseases after excluding women with a history of other diseases from the two groups.

Outcomes*	No. cases <sup>1</sup> (%)	Unadjusted model	Adjusted model 1	Adjusted model 2
<b>Categorical variables</b>		<b>OR [95% CI]</b>	<b>OR [95% CI]</b>	<b>OR [95% CI]</b>
<b>Infertility treatment</b>	19 (9.3)	1.39 [0.86,2.24]	1.28 [0.79,2.07]	1.26 [0.77,2.04]
<b>Gestational diabetes</b>	16 (7.8)	1.60 [0.96,2.68]	1.56 [0.93,2.62]	1.35 [0.80,2.29]
<b>Hospitalization during pregnancy</b>	37 (17.6)	1.31 [0.91,1.87]	1.39 [0.97,1.99]	1.37 [0.96,1.97]
<b>Induction of labor</b>				
Spontaneous labor		1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Induction	43 (20.5)	1.16 [0.82,1.63]	1.17 [0.83,1.65]	1.10 [0.78,1.56]
Prelabor caesarean section	18 (8.6)	1.15 [0.70,1.88]	1.08 [0.66,1.78]	1.00 [0.61,1.65]
<b>Mode of birth</b>				
Vaginal delivery		1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Assisted delivery**	30 (14.3)	1.10 [0.74,1.64]	1.14 [0.75,1.73]	1.14 [0.75,1.74]
Caesarean section	36 (17.1)	1.07 [0.74,1.55]	1.03 [0.70,1.49]	0.95 [0.65,1.39]
<b>Premature rupture of membranes</b>	30 (14.5)	1.52 [1.03,2.25] <sup>a</sup>	1.51 [1.01,2.26] <sup>a</sup>	1.51 [1.01,2.25] <sup>a</sup>
<b>Birth weight categories***</b>				
AGA		1.00 (Reference)	1.00 (Reference)	NA
SGA	15 (7.1)	0.78 [0.46,1.33]	0.82 [0.48,1.40]	
LGA	21 (10.0)	0.99 [0.63,1.58]	0.99 [0.63,1.56]	
<b>Quantitative variables</b>		<b>β [95% CI]</b>	<b>β [95% CI]</b>	<b>β [95% CI]</b>
<b>Gestational age (amenorrhea weeks)</b>		0.07 [-0.11,0.26]	0.07 [-0.12,0.26]	0.05 [-0.14,0.24]
<b>Birth weight (g)</b>		45.17 [-19.19,109.5]	21.88[-31.95,75.71]	7.02 [-46.33,60.37]
<b>Birth length (cm)</b>		0.39 [0.09,0.70] <sup>a</sup>	0.28 [0.02,0.54] <sup>a</sup>	0.23 [0.03,0.49]
<b>Head circumference (cm)</b>		-0.02 [-0.22,0.19]	-0.06 [-0.25,0.12]	-0.10 [-0.28,0.08]

<sup>1</sup>N: number of cases in pre-pregnancy thyroid group after excluding other pathologies before adjustment.

Model 1: adjusted on maternal education level, maternal age, parity, smoking during pregnancy and infant sex and gestational age for head circumference, birth weight and birth length.

Model 2: model 1 and additional adjustment for BMI as a continuous variable.

\* Maximal N for outcome in unadjusted model (N=14,258) and minimal N in adjusted model 2 (N=12,701). When the sample was restricted to women included in the 3 models, results were similar as above for all 3 models.

\*\* Assisted delivery: forceps, spatulas, vacuum

## Pre-pregnancy thyroid diseases

\*\*\* Customized standard to assess fetal growth: SGA, small for gestational age ( $< 10^{\text{th}}$  percentile); AGA, appropriate for gestational age ( $10^{\text{th}}$  to  $90^{\text{th}}$  percentile); LGA, large for gestational age ( $>90^{\text{th}}$  percentile). (see methods).

<sup>a</sup> $p < .05$ . NA: not applicable because the model is already adjusted for BMI



Table 4: Comparison of outcomes for women without pre-pregnancy thyroid diseases and with pre-pregnancy hypothyroidism§ (hyperthyroidism or unspecified thyroid diseases excluded)

<b>Fertility and pregnancy complications</b>	<b>N</b>	<b>No pre-pregnancy thyroid diseases (N=16,122)</b>	<b>Pre-pregnancy hypothyroidism (N=196)</b>	<b>P-value</b>	<b>Adjusted model 2</b>
<b>Infertility treatment</b>	16,155	7.0 (1124)	12.0 (23)	0.007	1.55 [0.99,2.43]
<b>Gestational diabetes</b>	15,752	7.5 (1165)	12.4 (24)	0.010	1.24 [0.78,1.95]
<b>Gestational age at birth (amenorrhea weeks)</b>	16,225	39.6 ± 1.4	39.6 ± 1.3	0.87	-0.04 [-0.24,0.16]
<b>Hospitalization during pregnancy</b>	16,225	15.3 (2455)	16.3 (32)	0.70	1.10 [0.75,1.61]
<b>Induction of labor</b>	16,201			0.31	
Spontaneous labor		72.1 (11535)	69.4 (136)		1.00 (Reference)
Induction		19.3 (3084)	18.9 (37)		0.90 [0.62,1.30]
Prelabor caesarean section		8.7 (1386)	11.7 (23)		1.11 [0.70,1.75]
<b>Mode of delivery</b>	16,078			0.21	
Vaginal delivery		69.7 (11073)	64.6 (126)		1.00 (Reference)
Assisted delivery*		12.9 (2041)	13.3 (26)		1.11 [0.71,1.72]
Caesarean section		17.4 (2769)	22.1 (43)		1.12 [0.78,1.60]
<b>Premature rupture of membranes</b>	15,991	9.8 (1553)	14.5 (28)	0.030	1.49 [0.99,2.27]
<b>Birth weight (g)</b>	16,121	3334.8 ± 478.4	3366.8 ± 467.8	0.35	-0.20 [-55.9,55.5]
<b>Birth length (cm)</b>	14,897	49.6 ± 2.1	49.8 ± 2.1	0.34	0.02 [-0.25,0.29]
<b>Head circumference (cm)</b>	14,806	34.4 ± 1.4	34.3 ± 1.4	0.34	-0.20 [-0.39,-0.01]
<b>Birth weight categories**</b>	15,851			0.86	
SGA		9.3 (1459)	8.2 (16)		NA
AGA		80.8 (12646)	81.5 (159)		
LGA		9.9 (1551)	10.3 (20)		

§ pre-pregnancy hypothyroidism due to a disease or as a potential side effect of treatment (Hashimoto's disease, hypothyroidism unspecified, no thyroid, thyroidectomy, thyroid cancer)

Model 2: adjusted on maternal education level, maternal age, parity, smoking during pregnancy, BMI and infant sex and gestational age for head circumference, birth weight and birth length.

\* Assisted delivery: forceps, spatulas, vacuum

\*\* A customized standard to assess fetal growth: SGA, small for gestational age (< 10<sup>th</sup> percentile); AGA, appropriate for gestational age (10<sup>th</sup> to 90<sup>th</sup> percentile); LGA, large for gestational age (>90<sup>th</sup> percentile) (see methods)

Table 5: Multivariable analysis of pregnancy and birth outcomes for women with pre-pregnancy hypothyroidism§ but no other diseases compared to women without pre-pregnancy thyroid nor other diseases

Outcomes*	No. cases <sup>1</sup> (%)	No adjustment	Adjusted model 1	Adjusted model 2
Qualitative variables		OR [95% CI]	OR [95% CI]	OR [95% CI]
<b>Infertility treatment</b>	16 (11.0)	1.68 [1.00,2.84]	1.52 [0.89,2.58]	1.49 [0.87,2.53]
<b>Gestational diabetes</b>	11 (7.5)	1.54 [0.83,2.86]	1.51 [0.81,2.81]	1.24 [0.66,2.34]
<b>Hospitalization during pregnancy</b>	22 (14.8)	1.06 [0.67,1.67]	1.13 [0.72,1.79]	1.11 [0.70,1.75]
<b>Induction of labor</b>				
Spontaneous labor		1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Induction	28 (18.8)	1.04 [0.69,1.58]	1.05 [0.69,1.60]	0.96 [0.63,1.47]
Prelabor caesarean section	13 (8.7)	1.14 [0.64,2.04]	1.09 [0.61,1.95]	0.96 [0.53,1.73]
<b>Mode of birth</b>				
Vaginal delivery		1.00 (Reference)	1.00 (Reference)	1.00 (Reference)
Assisted delivery**	24 (16.1)	1.28 [0.82,2.01]	1.33 [0.83,2.14]	1.31 [0.82,2.11]
Caesarean section	26 (17.4)	1.13 [0.73,1.74]	1.11 [0.72,1.73]	0.99 [0.64,1.55]
<b>Premature rupture of membranes</b>	25 (17.1)	1.86 [1.20,2.86] <sup>a</sup>	1.82 [1.16,2.84] <sup>a</sup>	1.79 [1.14,2.80] <sup>b</sup>
<b>Birth weight categories***</b>				
AGA		1.00 (Reference)	1.00 (Reference)	NA
SGA	11 (7.4)	0.8 [0.43,1.49]	0.83 [0.45,1.55]	
LGA	14 (9.4)	0.93 [0.53,1.62]	0.93 [0.53,1.62]	
<b>Quantitative variables</b>		$\beta$ [95% CI]	$\beta$ [95% CI]	$\beta$ [95% CI]
<b>Gestational age (amenorrhea weeks)</b>		0.03 [-0.19,0.25]	0.03 [-0.20,0.25]	0.004 [-0.22,0.23]
<b>Birth weight (g)</b>		29.54 [-46.89,105.97]	14.42 [-49.37,78.22]	-8.53 [-71.62,54.57]
<b>Birth length (cm)</b>		0.31 [-0.04,0.67]	0.23 [-0.08,0.53]	0.16 [-0.14,0.47]
<b>Head circumference (cm)</b>		-0.12 [-0.36,0.11]	-0.17 [-0.39,0.04]	-0.23 [-0.44,-0.01] <sup>b</sup>

§ pre-pregnancy hypothyroidism due to a disease or as a potential side effect of treatment (Hashimoto's disease, hypothyroidism unspecified, no thyroid, thyroidectomy, thyroid cancer)

<sup>1</sup>N: number of cases in pre-pregnancy hypothyroidism diseases group before adjustment

Model 1: adjusted on maternal education level, maternal age, parity, smoking during pregnancy and infant sex and gestational age for head circumference, birth weight and birth length.

Model 2: model 1 and additional adjustment for BMI as a continuous variable

\* Maximal N for outcome in unadjusted model (N=14,197) and minimal N in adjusted model2 (N=12,646). When the sample was restricted to subjects included in the 3 models, results were similar as above for all 3 models.

\*\*Forceps, spatulas, vacuum

## Pre-pregnancy thyroid diseases

\*\*\* Customized standard to assess fetal growth: SGA, small for gestational age (< 10<sup>th</sup> percentile); AGA, appropriate for gestational age (10<sup>th</sup> to 90<sup>th</sup> percentile); LGA, large for gestational age (>90<sup>th</sup> percentile). (see methods)

<sup>a</sup> p<0.01   <sup>b</sup> p<0.05. NA: not applicable because the model is already adjusted for BMI.

Supplementary Table S1: Outcomes for women with and without pre-pregnancy thyroid diseases.

<b>Fertility and pregnancy complications</b>	<b>N</b>	<b>No pre-pregnancy thyroid diseases (N=16,122)</b>	<b>Pre-pregnancy thyroid diseases (N=273)</b>	<b>P-value</b>
<b>Infertility treatment</b>	16,230	7.0 (1124)	11.7 (31)	0.004
<b>Gestational diabetes</b>	15,826	7.5 (1165)	11.9 (32)	0.006
<b>Gestational age at birth (amenorrhea weeks)</b>	16,302	39.6 ± 1.4	39.7 ± 1.3	0.73
<b>Hospitalization during pregnancy</b>	16,301	15.3 (2455)	18.8 (51)	0.12
<b>Induction of labor</b>	16,277			0.32
Spontaneous labor		72.1 (11535)	68.8 (187)	
Induction		19.3 (3084)	20.2 (55)	
Pre-labor caesarean section		8.7 (1386)	11.0 (30)	
<b>Mode of delivery</b>	16,154			0.45
Vaginal delivery		69.7 (11073)	66.8 (181)	
Assisted delivery*		12.9 (2041)	12.9 (35)	
Caesarean section		17.4 (2769)	20.3 (55)	
<b>Premature rupture of membranes</b>	16,067	9.8 (1553)	12.3 (33)	0.18
<b>Birth weight (g)</b>	16,198	3334.8 ± 478.4	3376 ± 460.3	0.16
<b>Birth length (cm)</b>	14,967	49.6 ± 2.1	49.9 ± 2.0	0.05
<b>Head circumference (cm)</b>	14,875	34.4 ± 1.4	34.4 ± 1.4	0.96
<b>Birth weight categories**</b>	15,926			0.68
SGA		9.3 (1459)	7.8 (21)	
AGA		80.8 (12646)	81.9 (221)	
LGA		9.9 (1551)	10.4 (28)	

Data are % (n) or mean ± SD.

\* Assisted delivery: forceps, spatulas, and vacuum

\*\*A customized standard to assess fetal growth: SGA, small for gestational age (< 10<sup>th</sup> percentile); AGA, appropriate for gestational age (10<sup>th</sup> to 90<sup>th</sup> percentile); LGA, large for gestational age (>90<sup>th</sup> percentile (see methods))